Google Groups no longer supports new Usenet posts or subscriptions. Historical content remains viewable.
Dismiss
Generic Drugs Win Landmark Judgment
5 views
Skip to first unread message
Vanden
Apr 1, 2013, 9:57:17 AM4/1/13
to
India’s Supreme Court ruled against the Swiss pharmaceutical company
Novartis on Monday in a landmark judgment with significant implications
for India’s giant generic drugs industry.
“This means millions of patients in developing countries can go to sleep
tonight knowing their drugs are on the way from India,” said Leena
Menghaney, a lawyer with the Access to Essential Medicines Campaign of
Medecins Sans Frontieres (Doctors Without Borders). Globally more than
10 million people living with HIV-AIDS rely on Indian generic
medications, including many who are treated by MSF; the fate of their
drugs hung in the balance in this decision, which pitted Novartis
against the Government of India’s patenting system.
Novartis on Monday in a landmark judgment with significant implications
for India’s giant generic drugs industry.
“This means millions of patients in developing countries can go to sleep
tonight knowing their drugs are on the way from India,” said Leena
Menghaney, a lawyer with the Access to Essential Medicines Campaign of
Medecins Sans Frontieres (Doctors Without Borders). Globally more than
10 million people living with HIV-AIDS rely on Indian generic
medications, including many who are treated by MSF; the fate of their
drugs hung in the balance in this decision, which pitted Novartis
against the Government of India’s patenting system.
Vanden
Apr 1, 2013, 9:57:17 AM4/1/13
to
India=E2=80=99s Supreme Court ruled against the Swiss pharmaceutical comp=
any=20
Novartis on Monday in a landmark judgment with significant implications=20
for India=E2=80=99s giant generic drugs industry.
=E2=80=9CThis means millions of patients in developing countries can go t=
o sleep=20
tonight knowing their drugs are on the way from India,=E2=80=9D said Leen=
a=20
Menghaney, a lawyer with the Access to Essential Medicines Campaign of=20
Medecins Sans Frontieres (Doctors Without Borders). Globally more than=20
10 million people living with HIV-AIDS rely on Indian generic=20
medications, including many who are treated by MSF; the fate of their=20
drugs hung in the balance in this decision, which pitted Novartis=20
against the Government of India=E2=80=99s patenting system.
any=20
Novartis on Monday in a landmark judgment with significant implications=20
for India=E2=80=99s giant generic drugs industry.
=E2=80=9CThis means millions of patients in developing countries can go t=
o sleep=20
tonight knowing their drugs are on the way from India,=E2=80=9D said Leen=
a=20
Menghaney, a lawyer with the Access to Essential Medicines Campaign of=20
Medecins Sans Frontieres (Doctors Without Borders). Globally more than=20
10 million people living with HIV-AIDS rely on Indian generic=20
medications, including many who are treated by MSF; the fate of their=20
drugs hung in the balance in this decision, which pitted Novartis=20
against the Government of India=E2=80=99s patenting system.
Vanden
Apr 3, 2013, 8:42:50 AM4/3/13
to
Vanden wrote:
> India?s Supreme Court ruled against the Swiss pharmaceutical company
>
> ?This means millions of patients in developing countries can go to sleep
> tonight knowing their drugs are on the way from India,? said Leena
By Rohit Bansal
Business
The Pioneer
http://www.dailypioneer.com
Wednesday, April 3, 2013
Novartis, the Swiss drug maker, claimed Monday that
research and innovation stand discouraged, if not ruined,
in India. The company carped after losing a long-drawn
legal battle in the Supreme Court to protect the patent
of Glivec, an anti-cancer block buster.
The protest implied that India’s apex court has bought
the ‘generic’ lobby’s accusation where Novartis was
merely “ever greening” the compound (imatinib); when, in
fact, the improvements achieved were considered
significant enough in 40 countries.
Novartis’s sub text is that fearing a spate of compulsory
licensing, pharma and non-pharma stars on the global
firmament might overfly India.The premise is pernicious,
because it paints the two judges of the Supreme Court as
anti-innovation medievalists.
My own sense is that no judge in India is immune to the
compelling logic of ‘innovation.’ I’ve found them deeply
conscious of the fact that the pipeline of new drug
discoveries can’t be clogged by a few desi thugs citing
lower pricing as an entitlement to steal research by
multinational companies. Our judges are equally aware
that Indian companies – irrespective of their ‘generic’
stereotyping – don’t just possess patents, they need to
protect them, including in markets outside the
territorial jurisdiction of Indian courts.
Continues at:
http://www.dailypioneer.com/columnists/business/eg-for-novartis.html
> India?s Supreme Court ruled against the Swiss pharmaceutical company
> Novartis on Monday in a landmark judgment with significant implications
> for India?s giant generic drugs industry.
>
> ?This means millions of patients in developing countries can go to sleep
> tonight knowing their drugs are on the way from India,? said Leena
> Menghaney, a lawyer with the Access to Essential Medicines Campaign of
> Medecins Sans Frontieres (Doctors Without Borders). Globally more than
> 10 million people living with HIV-AIDS rely on Indian generic
> medications, including many who are treated by MSF; the fate of their
> drugs hung in the balance in this decision, which pitted Novartis
> against the Government of India?s patenting system.
> Medecins Sans Frontieres (Doctors Without Borders). Globally more than
> 10 million people living with HIV-AIDS rely on Indian generic
> medications, including many who are treated by MSF; the fate of their
> drugs hung in the balance in this decision, which pitted Novartis
By Rohit Bansal
Business
The Pioneer
http://www.dailypioneer.com
Wednesday, April 3, 2013
Novartis, the Swiss drug maker, claimed Monday that
research and innovation stand discouraged, if not ruined,
in India. The company carped after losing a long-drawn
legal battle in the Supreme Court to protect the patent
of Glivec, an anti-cancer block buster.
The protest implied that India’s apex court has bought
the ‘generic’ lobby’s accusation where Novartis was
merely “ever greening” the compound (imatinib); when, in
fact, the improvements achieved were considered
significant enough in 40 countries.
Novartis’s sub text is that fearing a spate of compulsory
licensing, pharma and non-pharma stars on the global
firmament might overfly India.The premise is pernicious,
because it paints the two judges of the Supreme Court as
anti-innovation medievalists.
My own sense is that no judge in India is immune to the
compelling logic of ‘innovation.’ I’ve found them deeply
conscious of the fact that the pipeline of new drug
discoveries can’t be clogged by a few desi thugs citing
lower pricing as an entitlement to steal research by
multinational companies. Our judges are equally aware
that Indian companies – irrespective of their ‘generic’
stereotyping – don’t just possess patents, they need to
protect them, including in markets outside the
territorial jurisdiction of Indian courts.
Continues at:
http://www.dailypioneer.com/columnists/business/eg-for-novartis.html
Vanden
Apr 3, 2013, 8:42:50 AM4/3/13
to
Vanden wrote:
> India?s Supreme Court ruled against the Swiss pharmaceutical company
> tonight knowing their drugs are on the way from India,? said Leena
> India?s Supreme Court ruled against the Swiss pharmaceutical company
> Novartis on Monday in a landmark judgment with significant implications
> for India?s giant generic drugs industry.
>
> ?This means millions of patients in developing countries can go to sleep
>
> tonight knowing their drugs are on the way from India,? said Leena
> Menghaney, a lawyer with the Access to Essential Medicines Campaign of
> Medecins Sans Frontieres (Doctors Without Borders). Globally more than
> 10 million people living with HIV-AIDS rely on Indian generic
> medications, including many who are treated by MSF; the fate of their
> drugs hung in the balance in this decision, which pitted Novartis
> Medecins Sans Frontieres (Doctors Without Borders). Globally more than
> 10 million people living with HIV-AIDS rely on Indian generic
> medications, including many who are treated by MSF; the fate of their
> drugs hung in the balance in this decision, which pitted Novartis
0 new messages